Licensing manufacturers to produce generic versions of patented medicines for HIV and hepatitis C
- Grantee: Medicines Patent Pool
- Grant status: Open (phase 2)
- Amount Committed: US$ 29.6 million
- Amount Disbursed: grant ongoing
- Diseases: HIV, Hepatitis C
- Time Frame: 2016 - 2020
- Download Factsheet: [PDF, 500 KB]
Patents are intended to reward innovation. But unless licensed, a patent can also prevent production or sale of low-cost, quality-assured generic medicines or development of novel formulations.
The Medicines Patent Pool negotiates with patent holders for licences on their key patents for HIV and hepatitis C medicines. These licences grant permission for low-cost manufacturers to develop, manufacture and sell these medicines in developing countries, even where patents exist. Competition brings prices down, and the licences also provide the freedom to develop new formulations.
Results So Far:
- 1 direct-acting antiviral for hepatitis C
- 12 antiretrovirals licensed
- 12 generic suppliers
- 121 countries receiving firstline antiretrovirals from MPP generic partners
- 86% average price drop of first-line HIV medicines
- 3.5 billion doses of HIV treatment
The total direct global economic savings generated by the MPP are estimated to be US$ 2.2 billion by 2028, representing an estimated cost-benefit ratio of 1: 40. For every dollar spent, the global community gains US$ 40.
Contact information of the UNITAID grant manager for this grant
Name: Romane Theoleyre
Related projects that have pages on the UNITAID website: